Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live

Johnson & Johnson & Kenvue

7 shared events · Importance 3 · Last updated Jul 28, 2026

Importance
3
Shared Events
7
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
100
Regulatory
Johnson & Johnson: Johnson & Johnson is being sued by United States — Texas for allegedly hiding Tylenol's risks and deceptively marketing it. The lawsuit also claims Johnson & Johnson fraudulently transferred liabilities to Kenvue.
Kenvue: Kenvue, a spin-off of Johnson & Johnson, is a primary defendant in the United States — Texas lawsuit, accused of deceptively marketing Tylenol and facing claims of liability transfer from Johnson & Johnson. Kenvue's shares fell following the news.
Oct 28, 2025 · 20 articles
89
Business
Johnson & Johnson: Johnson & Johnson is facing a mass class-action lawsuit in the United Kingdom and ongoing litigation in the United States over allegations that its talc-based products caused cancer due to asbestos contamination. The company has been ordered to pay significant damages in US cases and faces a potential £1 billion liability in the UK.
Kenvue: Kenvue, formerly Johnson & Johnson's consumer health unit, retained responsibility for talc-related litigation outside the United States and Canada after its spin-off in 2023. It is named as a defendant in the UK lawsuit and maintains that its talc products are safe and asbestos-free.
Oct 16, 2025 · 14 articles
55
Business
Johnson & Johnson: Johnson & Johnson spun off Kenvue two years prior to this acquisition, aiming to make its pharmaceutical and medical device divisions more nimble.
Kenvue: Kenvue is being acquired by Kimberly-Clark for $48.7 billion, providing a significant premium to its shareholders. Kenvue's stock surged after the announcement, despite facing scrutiny over Tylenol and activist investor pressure.
Nov 03, 2025 · 10 articles
45
Regulatory
Johnson & Johnson: Former parent of Kenvue; spun off in 2023, not directly involved but legacy exposure.
Kenvue: Primary defendant; faces revived lawsuits alleging failure to warn about autism/ADHD risk. Stock fell 1% on ruling.
Jul 13, 2026 · 23 articles
32
Business
Johnson & Johnson: Johnson & Johnson is the defendant proposing the $5.5 billion settlement to resolve most talc lawsuits, which could end a decade-long legal battle and reduce uncertainty.
Kenvue: Kenvue, J&J's former consumer health business, holds liability for Johnson's baby powder outside North America but is not directly involved in the U.S. settlement.
Jul 27, 2026 · 82 articles
24
Business
Johnson & Johnson: Parent of Kenvue; mentioned as part of Anandani's background, no direct impact.
Kenvue: Anandani's previous employer; loses its India MD but no direct impact on Kenvue.
Jul 20, 2026 · 24 articles
0
Business
Dec 23, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Johnson & Johnson and Kenvue interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.